It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children. Although it is widely agreed that an RSV vaccine should induce both mucosal and systemic antibody responses, little is known about the B cell response to RSV in mucosa-associated lymphoid tissues. Here, we analyze this response by isolating 806 RSV F-specific antibodies from paired adenoid and peripheral blood samples from 4 young children. Overall, the adenoid-derived antibodies show higher binding affinities and neutralization potencies compared to antibodies isolated from peripheral blood. Approximately 25% of the neutralizing antibodies isolated from adenoids originate from a unique population of IgM+ and/or IgD+ memory B cells that contain a high load of somatic mutations but lack expression of classical memory B cell markers. Altogether, the results provide insight into the local B cell response to RSV and have implications for the development of vaccines that stimulate potent mucosal responses.
Here, the authors isolate over 800 RSV F-specific antibodies from paired nasopharyngeal tonsil and peripheral blood samples from four young children undergoing adenoidectomy and find that adenoid derived antibodies have overall higher binding affinities and neutralization potencies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Adimab LLC, Lebanon, USA
2 Geisel School of Medicine at Dartmouth, Department of Pediatrics, Hanover, USA (GRID:grid.254880.3) (ISNI:0000 0001 2179 2404)
3 Adimab LLC, Lebanon, USA (GRID:grid.254880.3)
4 Geisel School of Medicine at Dartmouth, Department of Surgery, Hanover, USA (GRID:grid.254880.3) (ISNI:0000 0001 2179 2404)